Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Symphogen has published data relating to its Sympress II technology in the March 20, 2010 online edition of Molecular Biotechnology by Nielsen LS et al, demonstrating its ability to enable cost-effective production of recombinant polyclonal antibodies (rpAb) and antibody mixtures with batch-to-batch consistency.
Subscribe to our email newsletter
Symphogen believes Sympress II technology could supply drug product for large indications such as cancer and infectious disease.
The Sympress II results demonstrated single-batch production of compositions with as many as six antibodies with a controlled and appropriate distribution in the final product.
Symphogen employs target-specific rpAbs, which represent a new generation of antibodies that mimic the diversity, specificity, and binding capability of the natural human immune system. Such rpAb preparations contain several specific antibodies, all of which in the Sympress II production system can be produced in the same culture vessel.
The Sympress II technology takes advantage of industry standard fed batch manufacturing processes for controlled production of recombinant polyclonal compositions.
Symphogen said that Sympress II builds upon Symphogen’s earlier Sympress I technology, which has demonstrated highly reproducible, stable single batch production, but has a lower yield due to site-specific integration of a single antibody gene per cell making it best tailored for drug production to niche indications.
The Sympress II production system utilises a combination of random gene integration together with a new high producer Chinese Hamster Ovary (CHO) cell line, Enhanced Chinese Hamster Ovary (ECHO), as well as other improvements, which generated the same stability and reproducibility as the Sympress I technology and on top of that resulted in more than 10-fold higher yields.
Furthermore, the generation of rpAb compositions with completely different target specificities was demonstrated suggesting that the Sympress II production system is generally applicable to rpAb manufacturing for large indications.
Kirsten Drejer, CEO of Symphogen, said: “These published results indicate that Symphogen is now the only company that has overcome previous production limitations for rpAbs and so has enabled the cost effective single batch production at cost of goods sold that compares favorably with monoclonal antibody manufacturing.
“We very much look forward to deploying Sympress II in the manufacturing of the rpAbs in our pipeline as they proceed through preclinical and clinical trials.”